Patents Assigned to Infectious Disease Research Institute
-
Publication number: 20120114688Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising Leishmania antigens, in particular, SMT and NH antigens or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.Type: ApplicationFiled: November 7, 2011Publication date: May 10, 2012Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Ajay Bhatia, Steven G. Reed
-
Publication number: 20120039994Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: ApplicationFiled: October 20, 2011Publication date: February 16, 2012Applicant: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20110280902Abstract: Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more Leishmania antigens, or a variant thereof. Additionally, methods of screening a screening library for tandem repeat proteins that have immunogenic properties are disclosed. Vaccines and pharmaceutical compositions comprising polynucleotides, polypeptides, fusion proteins and variants thereof that may be used for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmaniasis infection are described.Type: ApplicationFiled: October 11, 2010Publication date: November 17, 2011Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Yasuyuki Goto, Steven G. Reed
-
Publication number: 20110070290Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: ApplicationFiled: July 26, 2010Publication date: March 24, 2011Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20110014274Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: ApplicationFiled: July 26, 2010Publication date: January 20, 2011Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20100317607Abstract: Compounds of a compound of compound of general formula (I) wherein X1, X2, A, R1R2, R3 and R4 are as defined herein; are useful as anti-mycobacterial agents, especially agents for the treatment of tuberculosis.Type: ApplicationFiled: June 24, 2008Publication date: December 16, 2010Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Graham Michael Wynne, Olivier De Moor, Peter David Johnson, Richard John Vickers
-
Publication number: 20100310602Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.Type: ApplicationFiled: June 4, 2010Publication date: December 9, 2010Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Steven G. Reed, Darrick Carter
-
Patent number: 7833534Abstract: Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more Leishmania antigens, or a variant thereof. Additionally, methods of screening a screening library for tandem repeat proteins that have immunogenic properties are disclosed. Vaccines and pharmaceutical compositions comprising polynucleotides, polypeptides, fusion proteins and variants thereof that may be used for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmaniasis infection are described.Type: GrantFiled: April 10, 2007Date of Patent: November 16, 2010Assignee: Infectious Disease Research InstituteInventors: Yasuyuki Goto, Steven G. Reed
-
Publication number: 20100136046Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.Type: ApplicationFiled: November 18, 2009Publication date: June 3, 2010Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Yasuyuki Goto, Steven G. Reed
-
Publication number: 20100129391Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infection.Type: ApplicationFiled: April 4, 2008Publication date: May 27, 2010Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Steven G. Reed, Rhea N. Coler, Gregory C. Ireton
-
Patent number: 7695925Abstract: Compositions comprising fusion polypeptides of T. cruzi epitopes are provided, together with methods for the use of such compositions in the diagnosis of T. cruzi infection and in screening blood supplies. Diagnostic kits comprising such compositions are also provided.Type: GrantFiled: November 2, 2006Date of Patent: April 13, 2010Assignees: Inbios International, Inc., Infectious Disease Research InstituteInventors: Raymond L. Houghton, Steven G. Reed, Syamal Raychaudhuri
-
Publication number: 20100008924Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.Type: ApplicationFiled: July 2, 2009Publication date: January 14, 2010Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Ajay Bhatia, Steven G. Reed
-
Publication number: 20090291099Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.Type: ApplicationFiled: May 15, 2009Publication date: November 26, 2009Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Yasuyuki Goto, Steven G. Reed
-
Publication number: 20090181078Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: ApplicationFiled: January 9, 2009Publication date: July 16, 2009Applicant: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20090041798Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise Leishmania sterol 24-c-methyltransferase (SMT) polypeptides, portions, variants and/or fusions, as well as polynucleotides encoding SMT polypeptides, portions, variants and/or fusions.Type: ApplicationFiled: July 11, 2008Publication date: February 12, 2009Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Steven Reed, Yasuyuki Goto
-
Publication number: 20080287362Abstract: Compositions comprising fusion polypeptides of T. cruzi epitopes are provided, together with methods for the use of such compositions in the diagnosis of T. cruzi infection and in screening blood supplies. Diagnostic kits comprising such compositions are also provided.Type: ApplicationFiled: November 2, 2006Publication date: November 20, 2008Applicants: InBios International, Inc., Infectious Disease Research InstituteInventors: Raymond L. Houghton, Steven G. Reed, Syamal Raychaudhuri
-
Publication number: 20080131466Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: ApplicationFiled: September 26, 2007Publication date: June 5, 2008Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20080107692Abstract: The invention provides antigenic T. cruzi polypeptides, polynucleotides, and fusions thereof, as well as compositions comprising same. Also provided are diagnostic kits and methods for the diagnosis of T. cruzi infection and in screening blood supplies.Type: ApplicationFiled: May 2, 2007Publication date: May 8, 2008Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventor: Steven Reed
-
Publication number: 20070237794Abstract: Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more Leishmania antigens, or a variant thereof. Additionally, methods of screening a screening library for tandem repeat proteins that have immunogenic properties are disclosed. Vaccines and pharmaceutical compositions comprising polynucleotides, polypeptides, fusion proteins and variants thereof that may be used for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmaniasis infection are described.Type: ApplicationFiled: April 10, 2007Publication date: October 11, 2007Applicant: The Infectious Disease Research InstituteInventors: Yasuyuki Goto, Steven Reed